**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 87564

**Manuscript Type:** CORRECTION

**Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”**

Roy S *et al*. Prebiotics, probiotics and synbiotics in IBD

Supriya Roy, Suneela Dhaneshwar

**Supriya Roy,** Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India

**Suneela Dhaneshwar,** Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai 410206, Maharashtra, India

**Author contributions:** Dhaneshwar S conceived the idea and designed the review article protocol, edited the final draft of the manuscript; Roy S collected the data and wrote the paper; and all authors reviewed and approved the manuscript.

**Corresponding author: Suneela Dhaneshwar, PhD, Academic Research, Director, Pharmacist, Professor,** Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai 410206, Maharashtra, India. suneeladhaneshwar@rediffmail.com

**Received:** August 16, 2023

**Revised:** August 25, 2023

**Accepted:** September 1, 2023

**Published online:**

**Abstract**

Correction to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; **29**: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”. In this article, a correction note is to be added.

**Key Words:** Ulcerative colitis; Crohn’s disease; Pouchitis; Dysbiosis; Microbiota; Inflammation

Roy S, Dhaneshwar S. Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”. *World J Gastroenterol* 2023; In press

**Core Tip:** This manuscript is to add a “correction note” to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; **29**: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”.

**TO THE EDITOR**

***Correction***

Correction to: Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; 29(14): 2078-2100.

In this article, a correction note is to be added[1]. The corresponding author received a mail from Dr. Claudio De Simone sharing his concern about a probiotic formulation VSL#3 which is mentioned in this review article. Dr. Claudio wishes us to publish a corrigendum. It is an earnest request that please incorporate the following correction note and publish a corrigendum regarding the same.

**Correction note:**

This review article includes references to several studies that investigated a probiotic formulation formerly marketed as VSL#3 which is currently, generically referred to as the “De Simone Formulation”. It is important to note that the current product marketed as VSL#3 differs from the De Simone Formulation as also stated by the federal court of Maryland in the Civil Action, No. TDC-15-1356. They are distinct probiotic formulations with different compositions and characteristics. Currently, the De Simone Formulation is accessible under Vivomixx (in Europe) and Visbiome (in the United States) brand names.

**REFERENCES**

1 **Roy S**, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; **29**: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 16, 2023

**First decision:** August 25, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Salvadori M, Italy; Zhu L, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR